These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 26497726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.
    J Clin Oncol; 2015 Apr 10; 33(11):1243-51. PubMed ID: 25732167
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.
    Eur Urol; 2019 Apr 10; 75(4):676-683. PubMed ID: 30497883
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.
    JAMA Oncol; 2016 Apr 10; 2(4):500-7. PubMed ID: 26720632
    [Abstract] [Full Text] [Related]

  • 10. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
    Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, Adolfsson J, Robinson D, Stattin P.
    Eur Urol; 2017 Dec 10; 72(6):920-928. PubMed ID: 28711383
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
    Young JWS, Sutradhar R, Rangrej J, Marras C, Fleshner N, Alibhai SMH.
    World J Urol; 2017 Sep 10; 35(9):1417-1423. PubMed ID: 28204918
    [Abstract] [Full Text] [Related]

  • 14. Thromboembolic events following surgery for prostate cancer.
    Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, Stattin P, Adolfsson J.
    Eur Urol; 2013 Feb 10; 63(2):354-63. PubMed ID: 23021972
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL, O'Malley AJ, Freedland SJ, Smith MR.
    J Natl Cancer Inst; 2010 Jan 06; 102(1):39-46. PubMed ID: 19996060
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.